Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 16 April 2018

Indication(s)

Latuda is indicated for the treatment of schizophrenia in adults aged 18 years and over.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Hereditary ATTR amyloidosis

Hereditary ATTR amyloidosis

Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/002713
Orphan designation No
Date First Approved 21-03-2014
Type Medicinal product subject to medical prescription
Marketing authorisation holder Aziende Chimiche Riunite Angelini Francesco S.p.A.
Warnings

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reacti